Finanzas de United Therapeutics Corp (UTHR)UTHRUnited Therapeutics Corp

United Therapeutics Corporation (UTHR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Tyvaso DPI, accounting for 41.7% of total sales, equivalent to $326.60M. Other significant revenue streams include Remodulin and Nebulized Tyvaso. Understanding this composition is critical for investors evaluating how UTHR navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, United Therapeutics Corporation maintains a gross margin of 87.30%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 42.23%, while the net margin is 42.51%. These profitability ratios, combined with a Return on Equity (ROE) of 19.32%, provide a clear picture of how effectively UTHR converts its operational activities into shareholder value.

In the context of the broader market, UTHR competes directly with industry leaders such as ZLAB and BNTX. With a market capitalization of $21.43B, it holds a significant position in the sector. When comparing efficiency, UTHR's gross margin of 87.30% stands against ZLAB's 60.25% and BNTX's 8.14%. Such benchmarking helps identify whether United Therapeutics Corporation is trading at a premium or discount relative to its financial performance.

United Therapeutics has demonstrated strong financial performance with a gross margin of 87.30% in Q2 2026 and a net income of $333 million, reflecting robust profitability. The company has also shown consistent revenue growth, with Q2 2026 revenue reported at $783.3 million, indicating a healthy demand for its products.